


U.S. Application No.: 09/926,411
Reply to Office Action dated August 7, 2003

LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claim 1 (canceled)

Claim 2 (previously presented): The method of claim 6, wherein the macrolide compound is a tricyclo compound (I) of the following formula



wherein

adjacent pairs of R¹ and R², R³ and R⁴, and R⁵ and R⁶ each independently

- a) consist of two adjacent hydrogen atoms, wherein R² is optionally alkyl, or
- b) form another bond between carbon atoms binding with the members of each pair;

U.S. Application No.: 09/926,411
Reply to Office Action dated August 7, 2003

R⁷ is hydrogen atom, hydroxy, alkyloxy or protected hydroxy, or may form oxo with R¹;

R⁸ and R⁹ each independently are hydrogen atom or hydroxy;

R¹⁰ is hydrogen atom, alkyl, alkenyl, alkyl substituted by one or more hydroxy, alkenyl substituted by one or more hydroxy, or alkyl substituted by oxo;

X is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula -CH₂O-;

Y is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula N-NR¹¹R¹² or N-OR¹³;

R¹¹ and R¹² each independently are hydrogen atom, alkyl, aryl or tosyl;

R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²² and R²³ each independently are hydrogen atom or alkyl;

R²⁴ is an optionally substituted ring which optionally contains one or more hetero atom(s); and

n is 1 or 2,

wherein

Y, R¹⁰ and R²³ optionally form, together with the carbon atom they bind with, a saturated or unsaturated 5 or 6-membered heterocyclic group containing nitrogen atom, sulfur atom and/or oxygen atom, wherein the heterocyclic group may be substituted by one or more group(s) selected from the group consisting of alkyl, hydroxy, alkyloxy, benzyl, a group of the formula -CH₂Se(C₆H₅), and alkyl substituted by one or more hydroxy,

U.S. Application No.: 09/926,411
Reply to Office Action dated August 7, 2003

or a pharmaceutically acceptable salt thereof.

Claim 3 (previously presented): The method of claim 6 or claim 2, wherein said macrolide compound is FK506.

Claim 4 (currently amended): The method of claim 6, wherein said macrolide compound is administered in the form of a preparation suitable for local administration ~~to the eye as an eye drop.~~

Claim 5 (canceled)

Claim 6 (currently amended): A method for treating a dry eye, comprising administering ocular administration of an effective amount of a macrolide compound to a subject in need of the treatment of dry eye.

Claim 7 (canceled)

Claim 8 (previously presented): The method of claim 6, wherein said macrolide compound is administered in the form of a preparation suitable for local administration.

U.S. Application No.: 09/926,411
Reply to Office Action dated August 7, 2003

Claim 9 (previously presented): The method of claim 6, wherein said macrolide compound is administered in an amount of 0.0001 to 1000 mg.

Claim 10 (previously presented): The method of claim 9, wherein said macrolide compound is FK506.

Claim 11 (previously presented): The method of claim 6, wherein said macrolide compound is administered in an amount of 0.001 to 500 mg.

Claim 12 (previously presented): The method of claim 11, wherein said macrolide compound is FK506.

Claims 13-24 (canceled)